Table 3 Study population characteristics depending upon disease severity
From: Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
Variable | Mild/moderate patients (N = 6484) | Severe patients (N = 25,849) | Critical patients (N = 13,027) |
|---|---|---|---|
Age (mean, standard deviation) | 53.50, 18.78 | 62.51, 17.45 | 63.51, 16.18 |
Sex (male) | 2955 (45.57%) | 13,107 (50.71%) | 7472 (57.36%) |
African American | 1562 (24.09%) | 5768 (22.31%) | 2658 (20.40%) |
Caucasian | 1897 (29.26%) | 9956 (38.52%) | 5007 (38.44%) |
Hispanic | 2709 (41.78%) | 8780 (33.97%) | 4479 (34.38%) |
Other race | 316 (4.87%) | 1345 (5.20%) | 883 (6.78%) |
Alcohol use | 127 (1.96%) | 790 (3.06%) | 469 (3.60%) |
Nausea/vomiting | 179 (2.76%) | 445 (1.72%) | 132 (1.01%) |
Diarrhea | 187 (2.88%) | 770 (2.98%) | 398 (3.06%) |
Pancreatitis diagnosis | 21 (0.32%) | 219 (0.85%) | 126 (0.97%) |
Cholelithiasis/cholecystitis diagnosis | 66 (1.02%) | 566 (2.19%) | 311 (2.39%) |